Sangamo Therapeutics Inc
![Sangamo Therapeutics Inc](https://api.admiralmarkets.com/trade_icons/bright-128/SGMO.png)
Suletud
Sektor Tervishoid
0.72 -2.7
Ülevaade
Aktsiahinna muutus
24h
Min
0.71
Max
0.73
Müük | -7.4M 2M |
---|---|
Aktsiakasum | -0.34 |
Töötajad | 405 |
Soovitused | Osta |
---|---|
12 kuu keskmine prognoos | +281.94 upside |
Järgmine tulemuste avaldamine | 30. okt 2024 |
---|
Turukapital | -2.3M 114M |
---|---|
Eelmine avamishind | 3.42 |
Eelmine sulgemishind | 0.72 |
Uudiste sentiment
By Acuity
50%
50%
321 / 365 Pingereas Healthcare
Tehniline skoor
By Trading Central
Kindlus
Weak Bearish Evidence
Sangamo Therapeutics Inc Graafik
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Sangamo Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
281.94% tõus
12 kuu keskmine prognoos
Keskmine 2.75 USD 281.94%
Kõrge 5 USD
Madal 1 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Sangamo Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Sentiment
By Acuity
321 / 365 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
EBITDA
Ärikasum
$
Ettevõttest Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.